Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of RNK08954 in KRAS G12D-mutant metastatic pancreatic ductal adenocarcinoma
CTR20254089Phase 2Active
- Sponsor
- Ranok Therapeutics
- Start
- Oct 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RNK08954 in pancreatic adenocarcinoma (PDAC), sponsored by Ranok Therapeutics. Started Oct 2025; status: active.
02
Drugs
RNK08954
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20254089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254089.